Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Ablynx NV (ABLX) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/29/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"PREVIOUSLY ANNOUNCED TENDER OFFERS BY SANOFI TO ACQUIRE ABLYNX WILL COMMENCE ON APRIL 4, 2018 • Prospectus approved by the FSMA on March 27, 2018 and to be published on April 3, 2018 • Initial acceptance period will commence on April 4, 2018 and expire on May 4, 2018, subject to extension Paris, France and Ghent, Belgium - March 29, 2018 - Sanofi [Euronext: SAN; NYSE: SNY] and Ablynx [Euronext Brussels and Nasdaq: ABLX] announced today that on April 4, 2018, Sanofi will commence the previously announced tender offers to acquire all of the outstanding shares ), warrants and convertible bonds of Ablynx for: - EUR 45.00 per share or ADS - EUR 18.66 - EUR 41.79 per warrant 1 - EUR 393,700.78 per convertible bond 2 The tender offers, which are being made pursuant to the Heads of Agreement, date..."
03/27/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"ABLYNX ANNOUNCES TOPLINE RESULTS FROM THE PHASE II STUDY OF VOBARILIZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS GHENT, Belgium, 26 March 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that the Phase II dose-ranging study of vobarilizumab, the Company's anti-IL-6R Nanobody ® , did not meet the primary endpoint of dose response based on the modified BILAG-based combined lupus assessment at Week 24. The study enrolled 312 patients with moderate to severe, active seropositive systemic lupus erythematosus across five treatment arms . Demographics and baseline characteristics were similar across treatment arms, and reflective of a typical SLE population. Safety findings through Week 58 were favourable for vobarilizumab. Treatment-related serious adverse events were re..."
03/02/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ABLYNX COMMENCES DOSING IN ITS PHASE II STUDY OF ALX-0171 IN HOSPITALISED JAPANESE INFANTS WITH A RSV INFECTION"
02/16/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ABLYNX ANNOUNCES BOARD CHANGES GHENT, Belgium, 7 February 2018 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX] today announced that Dr Bo Jesper Hansen, acting as permanent representative of Orfacare Consulting GmbH, has decided to resign from the Board of Directors with immediate effect for personal reasons. Having contributed to Ablynx's recent M&A activities, and served on the Board since 2013, Dr Hansen will now focus on other opportunities. He will be succeeded by Dr Russell G. Greig, acting as a permanent representative of Greig Biotechnology Global Consulting Inc., who has been a non-executive Director of Ablynx since 2012, and has been unanimously elected by the Ablynx Board as the new Chairman. Dr Greig is an industry veteran and is currently Chairman of AM Pharma and MedEye , Sa...",
"ABLYNX ANNOUNCES OPTION EXERCISE BY SANOFI FOR TWO ADDITIONAL MULTI-SPECIFIC NANOBODY PRODUCT CANDIDATES GHENT, Belgium, 16 February 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that Sanofi has exercised its option to license two additional target combinations as part of the research collaboration signed in July 2017, focussed on developing and commercialising Nanobody ® -based therapeutics for the treatment of various immune-mediated inflammatory diseases. Under the terms of the agreement, Sanofi gains exclusive global rights to two additional multi-specific Nanobodies against selected targets and in return will pay Ablynx exercise fees totalling €13 million plus additional research funding. Multi-specific Nanobodies provide the ability to address different pathway o..."
01/29/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"SANOFI TO ACQUIRE ABLYNX FOR €3.9 BILLION",
"Notice Published by the Financial Services and Markets Authority Pursuant to Article 7 of the Royal Decree of 27 April 2007 on Takeover Offers published on January 29, 2018"
01/08/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ABLYNX ANNOUNCES BOARD CHANGES GHENT, Belgium, 8 January 2018 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX] today announced that Dr Peter Fellner, who has served as Chairman since 2013 1 , has decided to resign from the Board with immediate effect for personal reasons. He will be succeeded by Dr Bo Jesper Hansen, acting as permanent representative of Orfacare Consulting GmbH, who has been a Non-executive Director of Ablynx since November 2013, and has been unanimously elected by the Ablynx Board as the new Chairman. Dr Bo Jesper Hansen is a highly-accomplished industry veteran with significant expertise in orphan drug research and development, international marketing and commercialization and has extensive regulatory, pharmacovigilance, medical marketing and business development knowled..."
12/21/2017 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ABLYNX ANNOUNCES POSITIVE DATA FROM ITS JAPANESE ETHNO-BRIDGING STUDY OF CAPLACIZUMAB • Comparable pharmacokinetics observed in Japanese and Caucasian healthy volunteers • Caplacizumab was well-tolerated in all groups GHENT, Belgium, 21 December 2017 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX] today announced that the single and multiple dose Phase I study demonstrated comparable PK of caplacizumab in Japanese and Caucasian subjects. Caplacizumab is the Company's wholly-owned anti-von Willebrand factor Nanobody ® being developed for the treatment of acquired thrombotic thrombocytopenic purpura . The Phase I single centre study enrolled 60 healthy Japanese and Caucasian subjects and consisted of single ascending dose and multiple dose parts. At all doses studied, the PK of caplacizumab..."
12/12/2017 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"ABLYNX REPORTS ADDITIONAL CLINICALLY IMPORTANT BENEFITS OF CAPLACIZUMAB FROM ITS PHASE III HERCULES STUDY IN ACQUIRED TTP Additional results from the Phase III HERCULES study showed that treatment with caplacizumab resulted in:"
12/07/2017 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ABLYNX WILL HOST A WEBCAST TO DISCUSS ADDITIONAL DATA FROM ITS PHASE III HERCULES STUDY OF CAPLACIZUMAB IN ACQUIRED TTP FOLLOWING ASH LATE-BREAKING DATA PRESENTATION GHENT, Belgium, 7 December 2017 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX] announced today that the Ablynx management team will host a conference call and webcast to present additional data from the Phase III HERCULES study of caplacizumab in acquired thrombotic thrombocytopenic purpura , following its presentation by Professor Marie Scully in the late-breaking abstracts session at the 59 th Annual Meeting of the American Society of Hematology in Atlanta, GA, USA. The late-breaking data presentation will include positive topline results from the Phase III HERCULES study of caplacizumab announced on 2 October 2017 togethe..."
11/21/2017 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"RESULTS FROM THE PHASE III HERCULES STUDY OF CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP SELECTED FOR PRESENTATION IN THE LATE-BREAKING ABSTRACTS SESSION AT THE 2017 ASH ANNUAL MEETING"
11/16/2017 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ABLYNX ANNOUNCES RESULTS FOR THE FIRST NINE MONTHS OF 2017 AND A YEAR-TO-DATE BUSINESS UPDATE"
10/30/2017 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"ABLYNX CLOSES ON UNDERWRITERS' OPTION TO PURCHASE $30 MILLION OF ADDITIONAL SHARES IN THE U.S. INITIAL PUBLIC OFFERING"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy